Search Medical Condition
Please enter condition
Please choose location from dropdown

Villeneuve d'Ascq, France Clinical Trials

A listing of Villeneuve d'Ascq, France clinical trials actively recruiting patients volunteers.

RESULTS

Found (588) clinical trials

Assessment of Symptoms and Consequences of Coloanal Continuity Reconstruction

First of all, an information document will be given to the patients and their consent will be collected. Then, they will be registered through the online eCRF (or by FAX) and a study number will be given to each patient. The study will proceed with 2 stomatherapy consultations at one ...

Phase N/A

3.84 miles

Learn More »

French Language Validation of the 5-minutes Montreal Cognitive Assessment (MoCA)

The Montreal Cognitive Assessment (MOCA) is a test used to detect cognitive impairments. This test is available in different languages including french. A short version (the 5 minutes MOCA) has also been validated through a phone call use that allows to develop some epidemiological approaches. Nevertheless, this short version has ...

Phase N/A

3.84 miles

Learn More »

Is Caffeine an Environmental Modifier in Huntington's Disease?

The aim of the study is to establish if caffeine consumption is associated with the evolution of the disease in premanifest HD.

Phase N/A

3.84 miles

Learn More »

A Study to Assess the Efficacy and Safety of Risankizumab in Subjects With Moderately to Severely Active Crohn's Disease Who Failed Prior Biologic Treatment

The objective of Study M15-991 is to evaluate the efficacy and safety of risankizumab versus placebo during induction therapy in subjects with moderately to severely active CD.

Phase

3.84 miles

Learn More »

Evaluation of Short Antibiotic Combination Courses Followed by Aerosols in Cystic Fibrosis

The aim of this study is to investigate the efficacy of antibiotic therapy with any antibiotic (IV) and IV (Nebcin) tobramycin for 5 days followed by Solution for nebuliser inhalation (Tobi) for 9 days and antibiotic cures using 14 days of tobramycin IV. In the case of positive results, the ...

Phase

3.84 miles

Learn More »

Assesment of the Impact of a Nutritional Prevention Programme for Employees in Staggered Hours.

Staggered work affects about 20% of French employees and its health risks are now well known. They concern physical health (sleep disorders, weight gain, cancer, cardiovascular disorders, nutritional problems, etc.) and psychological health. Faced with these "alarming" findings, it is necessary to find ways of improvement and levers of action ...

Phase N/A

3.84 miles

Learn More »

Immunotherapy With Neo-adjuvant Chemotherapy for OVarian Cancer

The schedule is the following: In a first step a run-in phase of 6 patients will be conducted to test the safety and feasibility of the combination of durvalumab with standard carboplatin-paclitaxel chemotherapy. Cycle 1 : chemotherapy alone (day1) Cycle 2 : chemotherapy + durvalumab (day1) Cycle 3 : chemotherapy ...

Phase

3.84 miles

Learn More »

A Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Subjects With Moderately to Severely Active Crohn's Disease Who Have Inadequately Responded to or Are Intolerant to Biologic Therapy

The objective of this study is to evaluate the efficacy and safety of upadacitinib compared to placebo as induction therapy in subjects with moderately and severely active Crohn's disease (CD).

Phase

3.84 miles

Learn More »

Chemotherapy Intensification in Patients With High Lactate Dehydrogenase Values and Soluble Syndecan1 Levels

In first-line metastatic colorectal cancer (mCRC), baseline prognostic factors allowing death risk and strategy stratification are lacking. In this setting, a simple biological scoring system have recently been proposed, including LDH and CD138 binary status seric values, identifying one third of patients with worst prognostic. Intensified-chemotherapy strategies, combining 5-fluorouracile, Oxaliplatin, ...

Phase

3.84 miles

Learn More »

Assessment of the Efficacy of Bevacizumab in Combination With Folfiri as Second-line Treatment in Patients Suffering From an Advanced Inoperable Poorly Differentiated Neuroendocrine Carcinoma of an Unknown or Gastroentero-pancreatic Primary Cancer

Poorly differentiated neuroendocrine carcinomas (NEC) are a sub-group of aggressive neuroendocrine neoplasms (NEN). The most common primary sites are broncho-pulmonary and digestive. The gastroentero-pancreatic NECs (GEP-NEC) represent 7-21% of all of the NENs. Recent data on the initial presentation of GEP-NEC have been reported in two retrospective studies and a ...

Phase

3.84 miles

Learn More »